{"id":181298,"name":"SANOFI US SERVICES INC (FORMERLY KNOWN AS GENZYME CORPORATION)","slug":"sanofi-us-services-inc-formerly-known-as-genzyme-corporation","state":"DC","description":"A bio company focused on developing and applying advanced technologies in the life science","totalSpending":1870000,"filings":31,"yearlySpending":[{"year":2018,"income":250000},{"year":2019,"income":240000},{"year":2020,"income":240000},{"year":2021,"income":180000},{"year":2022,"income":300000},{"year":2023,"income":240000},{"year":2024,"income":180000},{"year":2025,"income":240000}],"firms":["TARPLIN, DOWNS & YOUNG, LLC"],"lobbyists":["RAISSA DOWNS","JENNIFER YOUNG","MICHELLE EASTON","ELIZABETH MURRAY","CHARLOTTE IVANCIC","PAMELA SMITH","EMILY MURRY","KIMBERLY BRANDT","MARGARET JOSEPH","PETER FISE","LAURA FRIEDEL","PARICK CARROLL"],"issues":["BUD","TAX","CPT","HCR","MMM",null],"sampleDescriptions":["budget resolution, reconciliation, deficit reduction, debt ceiling, apropriations\nH.R. 1625 - Consolidated Appropriations Act of 2018\nH.R. 1892 - Bipartisan Budget Act of 2018","orphan drug tax credit","Patent reform","PL 114-255 - 21st Century Cures, implementation\nH.R. 878/S. 204 - Right to Try Act\nH.R. 1231/S. 456 - RACE for Children Act\nH.R. 2430 - FDA Reauthorization Act of 2017\nH.R. 849/S. 260 - Protecting Seniors' Access to Medicare Act\n\n***no specific bills, importation, supply chain integrity, 304b, biosimilars, orphan drugs, newborn screening, expanded access, priority review, transparency, drug shortages, IPAB","***, no specific bill(s), Medicare Reimbursement, Medicaid Rebate, Medicaid Coverage and Reimbursement, quality indicators, coding, oncology, CMMI, home infusion, Least Costly alternative, Part B, ASP, insulin access, vaccines, flu","PL 114-255 - 21st Century Cures, implementation\nH.R. 878/S. 204 - Right to Try Act\nH.R. 1231/S. 456 - RACE for Children Act\nH.R. 2430 - FDA Reauthorization Act of 2017\nH.R. 849/S. 260 - Protecting Seniors' Access to Medicare Act\nS. 2852 - Pandemic and All Hazards Preparedness Act \nS.2315 - Over-the-Counter Drug Safety, Innovation, and Reform Act\n\n\n***no specific bills, importation, supply chain integrity, 304b, biosimilars, orphan drugs, newborn screening, expanded access, priority review, transparency, drug shortages, IPAB","***, no specific bill(s), Medicare Reimbursement, Medicaid Rebate, Medicaid Coverage and Reimbursement, quality indicators, coding, oncology, CMMI, home infusion, Least Costly alternative, Part B, ASP, insulin access, vaccines, flu, prescription drug access and affordability","budget resolution, reconciliation, deficit reduction, debt ceiling, apropriations\nH.R. 1625 - Consolidated Appropriations Act of 2018\nH.R. 1892 - Bipartisan Budget Act of 2018\nH.R. 6157 - HHS appropriations and continuing resolution","PL 114-255 - 21st Century Cures, implementation\nH.R. 878/S. 204 - Right to Try Act\nH.R. 1231/S. 456 - RACE for Children Act\nH.R. 2430 - FDA Reauthorization Act of 2017\nH.R. 849/S. 260 - Protecting Seniors' Access to Medicare Act\nS. 2852 - Pandemic and All Hazards Preparedness Act \nS.2315 - Over-the-Counter Drug Safety, Innovation, and Reform Act\nH.R. 6 - SUPPORT for Patients and Communities Act\n\n\n***no specific bills, importation, supply chain integrity, 304b, biosimilars, orphan drugs, newborn screening, expanded access, priority review, transparency, drug shortages, IPAB","budget resolution, reconciliation, deficit reduction, debt ceiling, appropriations\nH.R. 1625 - Consolidated Appropriations Act of 2018\nH.R. 1892 - Bipartisan Budget Act of 2018\nH.R. 6157 - HHS appropriations and continuing resolution\nH.R. 695 - Department of Defense Appropriations Act","no specific bills, Medicare Reimbursement, Medicaid Rebate, Medicaid Coverage and Reimbursement, quality indicators, coding, oncology, CMMI, Part B, ASP, insulin access, vaccines, flu, prescription drug access and affordability, transparency","budget resolution, reconciliation, deficit reduction, debt ceiling, appropriations\nH.J.Res. 31 - Consolidated Appropriations Act, 2019","H.R. 1781 - Payment Commission Data Act of 2019\nH.R. 938 - the BLOCKING Act of 2019\nH.R. 1520 - the Purple Book Continuity Act of 2019\nH.R. 1503 - the Orange Book Transparency Act of 2019\nH.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019\nH.R.269 - PAHPA Reauthorization and Advancing Innovation Act of 2019\n\nno specific bills, importation, supply chain integrity, 304b, biosimilars, orphan drugs, newborn screening, expanded access, priority review, transparency, drug shortages","H.R. 1781 - Payment Commission Data Act of 2019\nH.R. 269 - PAHPA Reauthorization and Advancing Innovation Act of 2019\nS. 97 - Affordable and Safe Prescription Drug Importation Act\nS. 1416 - Affordable Prescriptions For Patients Act of 2019 \nS. 1895 - Lower Health Care Costs Act\n\nno specific bills, importation, supply chain integrity, 304b, orphan drugs, newborn screening, expanded access, priority review, transparency, drug shortages, drug pricing, insulin, international reference pricing","deficit reduction, debt ceiling, appropriations, biodefense\nH.R. 2740 - HHS Appropriations, 2020\nH.R. 3164 - FDA Appropriations, 2020","deficit reduction, debt ceiling, appropriations, biodefense\nH.R. 2740 - HHS Appropriations, 2020\nH.R. 3164 - FDA Appropriations, 2020\nH.R. 4378 - Continuing Appropriations Act and Health Extenders Act","H.R. 1781 - Payment Commission Data Act of 2019\nH.R. 269 - PAHPA Reauthorization and Advancing Innovation Act of 2019\nS. 97 - Affordable and Safe Prescription Drug Importation Act\nS. 1416 - Affordable Prescriptions For Patients Act of 2019 \nS. 1895 - Lower Health Care Costs Act\nH.R. 3 - Lower Drug Costs Now Act\nS. 2543 - Prescription Drug Pricing Reduction Act\nH.R. 5333 - OTC Monograph Reform Act\n\nno specific bills, importation, supply chain integrity, 304b, orphan drugs, newborn screening, expanded access, priority review, transparency, drug shortages, drug pricing, insulin, international reference pricing","no specific bills, Medicare Reimbursement, Medicaid Rebate, Medicaid Coverage and Reimbursement, quality indicators, coding, oncology, CMMI, Part B, ASP, insulin access, vaccines, flu, prescription drug access and affordability, transparency, international reference pricing\n\nH.R. 3 - Lower Drug Costs Now Act\nS. 2543 - Prescription Drug Pricing Reduction Act","no specific bills, Medicare Reimbursement, Medicaid Rebate, Medicaid Coverage and Reimbursement, quality indicators, coding, oncology, CMMI, Part B, ASP, insulin access, vaccines, flu, prescription drug access and affordability, transparency, international reference pricing\n\nH.R. 3 - Lower Drug Costs Now Act\nS. 2543 - Prescription Drug Pricing Reduction Act\nS. 3013 - Encouraging Innovative Benefit Design to Lower Costs for Seniors Act\nS. 3129 - Lower Costs, More Cures Act of 2019","deficit reduction, debt ceiling, appropriations, biodefense\nH.R. 4378 - Continuing Appropriations Act and Health Extenders Act\nH.R. 1865 - Further Consolidated Appropriations Act, 2020\nH.R. 3055 - Further Continuing Appropriations Act, 2020, and Further Health Extenders Act"],"years":[2018,2019,2020,2021,2022,2023,2024,2025]}